Big Pharma More Willing To Cooperate On Neglected Disease Research But Funding Models Still Unclear
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Debate over how best to fund research and development of neglected diseases may be reshaped by changing patterns of cooperation among Big Pharma and non-industry groups